Vanessa Rouach

Dr. Vanessa Rouach


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Journal of Bone Oncology
Verified
Journal Article
Open access
VRVanessa Rouach
Vanessa Rouach
IGInbal Goldshtein
Inbal Goldshtein
IWIdo Wolf
Ido Wolf
RCRaphael Catane
Raphael Catane
Gabriel ChodickGabriel Chodick
Gabriel Chodick
DCDani Cohen
Dani Cohen
Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is available on alendronate, the most common oral agent for the treatment of post-menopausal osteoporosis, regarding the association with bone metastases. To examine the association between oral bisphosphonate exposure before cancer diagnosis and the risk of bone metastases in osteoporotic women diagnosed with early breast cancer. This historical cohort study was conducted at the oncology division at Tel Aviv Medical Center. The study population included post-menopausal women with early breast cancer, diagnosed between 2002 and 2012. Data on cancer characteristics, diagnosis of osteoporosis, prior bisphosphonate exposure and outcome were collected from medical files. Among 297 osteoporotic women identified, 145 (49%) were treated with bisphosphonates (alendronate in 90% of the cases) before cancer diagnosis. BP-treated women were significantly older than the BP-naïve ones (67.9 years vs 64.6 years, p = 0.01), but comparable in risk factors and disease characteristics. Over a mean follow up of 5.6 years, nine cases of bone metastases were identified, eight of them among BP-naïve patient (cumulative incidence of 9.9%) and one among BP-treated patients (0.7%). In a multivariable Cox's proportional hazards survival model the use of BP prior to cancer diagnosis was associated with a hazard ratio of 0.04 (95%CI:0.004-0.403, p = 0.006) for bone metastasis. The HR remained similar after further adjustment for tumor stage and cancer therapy. History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.

25 August 2023 in Journal of Bone Oncology
Verified
Journal Article
Open access
VRVanessa Rouach
Vanessa Rouach
YGYona Greenman
Yona Greenman
GCGabriel Chodick
Gabriel Chodick
IGInbal Goldshtein
Inbal Goldshtein
Several guidelines have been proposed to prevent aromatase inhibitors induced bone loss (AIBL), but there is scarce data on their endorsement in clinical practice. To assess bone health evaluation and fracture prevention in postmenopausal women with estrogen receptor (ER)-positive breast cancer after aromatase inhibitors (AI) initiation. An historical cohort analysis based on data from the cancer and osteoporosis Maccabi Health Services (MHS) registries from Jan 1st 2009 to Dec 31st 2020. Cases of estrogen receptor (ER)-positive breast cancer were extracted. Index date was set as the first aromatase inhibitors (AI) purchase. Variables such as age, BMI, smoking history, alcohol use, rheumatoid arthritis, diabetes, glucocorticosteroid use, previous fractures, BMD T-scores and purchases of AI and anti-resorptive agents were collected. Age under 50, previous cancer, prior major osteoporotic fractures and prior anti-resorptive treatment were exclusion criteria. Kaplan-Meier curves were generated to assess the time to outcomes. Multivariable Cox's proportional hazards survival model was performed. A total of 8617 women initiating AI were eligible. The median follow up was 6.1 years. The mean (SD) age at index was 62.8 (9.2), the mean (SD) BMI was 29.1 (5.6). The mean (SD) T-score was −1.3 (1.2) at the lumbar spine, −1.5 (0.9) at the femoral neck and −1.0 (1.0) at the total hip. Twenty percent had type 2 diabetes, 8.1 % were active smokers, 3.8% had rheumatoid arthritis and 1.2% were exposed to glucocorticoids. A total of 37% and 53% underwent a DXA scan at 1 and 2 years from AI initiation, and 12% and 17% were prescribed an anti-resorptive agent at 1 and 2 years from index. Advanced age was associated with a higher rate of evaluation and treatment, while obesity and diabetes were associated with a lower rate. The cumulative incidence of a major osteoporotic fracture was 8.8 and 15.8 % at 5 and 10 years, respectively. Despite the excess risk of fractures, bone health assessment and preventive treatment are still partial and postponed in breast cancer AI treated patients. Strategies to ensure appropriate care are needed.

4 August 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
VRVanessa Rouach
Vanessa Rouach
HGHilary Gortler
Hilary Gortler
YGYona Greenman
Yona Greenman
GCGabriel Chodick
Gabriel Chodick
IGInbal Goldshtein
Inbal Goldshtein
Purpose: To assess the comparative effectiveness of zoledronic acid vs. denosumab in prevention of major osteoporotic fractures and mortality among patients with type 2 diabetes.Methods: The study population was identified by crosslinking the diabetes and osteoporosis registries of a large healthcare organization in Israel. Demographics, Charlson Comorbidity Index (CCI), diabetes complications, bone mineral density (BMD) T-scores, hemoglobin A1c levels, eGFR, purchase of statins and anti-resorptive agents were collected. Exposure groups were matched using propensity score. Kaplan-Meier curves were generated to assess the time from treatment initiation to outcomes. Multivariable Cox’s proportional hazards survival models estimated hazard ratios (HR) and 95% CIs for each outcome.Results: Among 27503 patients with concurrent osteoporosis and type 2 diabetes, 627 (4.7%) received zoledronic acid and 502 (3.7%) denosumab. Prior to matching, the denosumab-treated patients were older (mean age 75.7 vs 71.9, p<0.01), had longer diabetes duration (mean 8.4 vs 7.2 years, p<0.01), and had a lower baseline eGFR (59.4 vs 75.3, p<0.01) than the zoledronic acid-treated patients. After matching, 415 pairs of subjects were included. The incidence of all examined outcomes was similar in the Zol and Dmab treatment groups, including 5-year cumulative incidence of fractures (38% vs 31%), death events (36% vs 41%), overall fracture risk (HR=1.17, 95% CI: 0.78 to 1.75), death risk (HR= 1.12, 95% CI:0.87 to 1.44), and mortality after a hip fracture (HR= 0.92, 95% CI:0.37-2.29).Conclusions: Our findings suggest comparability of Zoledronic Acid and Denosumab in managing osteoporotic fractures and mortality among patients with type 2 diabetes.

17 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GFGil Fridberg
Gil Fridberg
OAOdelia Amit
Odelia Amit
CKChen Karni
Chen Karni
DTDina Tshernichovsky
Dina Tshernichovsky
DSDavid Shasha
David Shasha
RRRon Ram
Ron Ram
Objectives—chronic graft vs. host disease (cGVHD) is associated with substantial morbidity and mortality. We aimed to analyze advances in treatment strategy and outcomes during the last decade due to the incorporation of novel immunosuppressive therapy (IST) drugs in the armamentarium. Methods—we retrospectively analyzed all patients > 18 years with cGVHD after their first hematopoietic cell transplantation (HCT) between 2012 and 2020 (n = 91), divided into three treatment periods: 2012–2014, 2015–2017, and 2018–2020 (groups 1, 2, and 3, respectively). Results—mean cumulative steroid dose and dose/total cGVHD-treatment days was lower in groups 2–3 compared to 1 (p = 0.008 and p = 0.042, respectively). The median IST-free survival was 79 (95%CI54–94) months, with more patients in group 3 (47% (95%CI 25–54%) discontinuing IST at 3 years, p = 0.1). Groups 2–3 compared to 1 had better glycemic control (p < 0.01), higher bone density (p = 0.06), and fewer cardiovascular events. The number of admissions/patient dropped from 0.7/year in group 1 to 0.24/year and 0.36/year in groups 2–3, respectively (p = 0.36). Employment reintegration was higher in groups 2–3 compared with 1 (p = 0.05) and so was earlier return to work (p = 0.01). There were no differences in survival outcomes. Conclusions—the incorporation of novel agents appears to be associated with reduced overall steroid burden, improved cGVHD control, and fewer long-term side effects.

3 December 2025 in JCEM Case Reports
Verified
Journal Article
Open access
VRVanessa Rouach
Vanessa Rouach
MYMichal Yacobi-Bach
Michal Yacobi-Bach
NRNeta Raz
Neta Raz
IDIdo Druckman
Ido Druckman
YGYona Greenman
Yona Greenman
ESElad Shemesh
Elad Shemesh
McCune-Albright syndrome (MAS) is a rare genetic disorder characterized by fibrous dysplasia of bone, café-au-lait skin pigmentation, and endocrine abnormalities. Adult presentation with spinal fibrous dysplasia, although previously reported, is uncommon and diagnostically challenging. We report 2 cases of MAS diagnosed in young women who initially presented with persistent back pain. Both patients underwent imaging studies that revealed multiple lytic lesions in the spine, raising concern for metastatic disease. Further evaluation confirmed the presence of polyostotic fibrous dysplasia without evidence of malignancy. Both patients had a history of precocious puberty, consistent with the syndrome's known manifestations. In 1 case, the diagnosis was supported by detection of a somatic GNAS variant using next-generation sequencing on DNA and RNA extracted from bone biopsy. The second patient declined genetic testing. These cases highlight the importance of considering MAS in the differential diagnosis of spinal lesions in young individuals, particularly when imaging reveals multifocal, expansile, and radiolucent bone lesions. Early recognition is essential for appropriate management, genetic counseling, and monitoring of potential endocrine complications.

3 February 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
VRVanessa Rouach
Vanessa Rouach
OROhad Regev
Ohad Regev
HGHilary Gortler
Hilary Gortler
YGYona Greenman
Yona Greenman
GCGabriel Chodick
Gabriel Chodick
IGInbal Goldshtein
Inbal Goldshtein
Purpose: To evaluate the real-world effectiveness of antiresorptive osteoporosis pharmacologic treatments on fracture incidence and survival in patients with type 2 diabetes mellitus (T2DM), with subgroup analysis by treatment route. Methods: We conducted a retrospective cohort study using a national registry of patients with T2DM and osteoporosis. Patients receiving antiresorptive treatments (oral or intravenous/subcutaneous [IV/SC]) were compared to untreated individuals using propensity score matching. The primary outcomes were major osteoporotic fracture (MOF) and all-cause mortality. Cox proportional hazards models were used to assess associations, including subgroup analyses by BMI and HbA1c. Results: Among 8,788 matched patients, treatment was associated with significantly lower mortality (adjusted HR 0.86; 95% CI: 0.78–0.94) but not with reduced fracture incidence (HR 1.11; 95% CI: 0.96–1.29). In the treated subgroup (N = 2,960), IV/SC therapy was associated with reduced fracture risk (HR 0.58; 95% CI: 0.35–0.94) but increased mortality (HR 1.63; 95% CI: 1.35–1.96) compared to oral treatment. Conclusion: In this real-world cohort of patients with type 2 diabetes and obesity, osteoporosis treatment was associated with improved survival but not reduced fracture risk. Injectable therapies offered greater fracture protection but were linked to higher mortality, likely due to confounding by indication. Poor adherence may limit the effectiveness of oral treatments in routine care. These findings underscore the need for individualized osteoporosis management strategies in high-risk diabetic populations and raise important considerations regarding the optimal route of administration in real-world settings.